Original Article
Visual Outcome of Vision
Threatening Diabetic Retinopathy after Various Treatment Modalities
Sidra
Shakil, M. Saleh Memon, P. S. Mahar, Abdul Fattah Memon, Muhammad Faisal Fahin,
Seema N. Mumtaz, Sikandar Ali Sheikh
Pak J Ophthalmol 2019, Vol. 35, No. 1
. . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .
See
end of article for authors
affiliations
..
.. Correspondence
to: P.S.
Mahar FRCS, DO, FRCOphth Professor & Dean Isra Postgraduate Institute of
Ophthalmology, Karachi. Email: salim.mahar@aku.edu |
Purpose: To determine
the visual outcome of laser treatment and intra-vitreal Avastin (Bevacizumab)
injection as mono-therapy or combined, in patients with Vision Threatening
Diabetic Retinopathy (VTDR). Study
Design: Quasi Experimental study with non-probability convenient
sampling. Place
& Duration of Study: Isra Postgraduate Institute of
Ophthalmology, Al-Ibrahim Eye Hospital, Karachi from January 2016 to December
2017. Material
& Methods: Patients with Diabetic retinopathy (DR) were graded according to
International clinical diabetic retinopathy & macular edema disease
severity scale. Patients with VTDR were offered Laser therapy, intra-vitreal
Avastin injection or both. Results: VTDR was
witnessed in 586 patients out of 1988 patients with DR. Out of which 108 had
Proliferative Diabetic Retinopathy (PDR), 382 had clinically significant
macular edema (CSME) and 96 had Advanced Diabetic Eye Disease (ADED). Laser
was done in 78 eyes, intravitreal Avastin was given in 340 eyes and combined
laser and Avastin were given in 35 eyes. When visual outcome was correlated
with treatment modalities, improvement was found in 248 eyes, deterioration
in 34 eyes and stabilization in 58 eyes
of Avastin group, whereas improvement was seen in 45 eyes,
deterioration in 15 eyes and stabilization in 18 eyes of laser group. In combined
treatment group, improvement was witnessed in 23 eyes, deterioration in 4
eyes and stabilization in 8 eyes. Conclusions: Visual outcome
of Avastin alone or combined with laser was found to be better than laser
treatment alone in stabilizing the visual acuity in patients with vision
threatening diabetic retinopathy. Keywords: Bevacizumab,
Laser, Intra vitreal Injection, Avastin. |
Diabetic retinopathy (DR) is an important complication of diabetes
and is a global cause of blindness. It is classified into non proliferative
diabetic retinopathy (NPDR), proliferative retinopathy (PDR) and diabetic
macular edema (DME). Involvement or threatening of the center of the macula is
termed clinically significant macular edema (CSME) by the Early Treatment diabetic
Retinopathy Study (ETDRS)1. In clinical situation, CSME has become
synonymous with DME. Worldwide, there are approximately 93 million people with
DR, Out of which 17 million have PDR and 21 million have DME2. In
Pakistan, based on National Survey of blindness carried out in 20073,
it was estimated that there were at least 90,000 to 100,000 adults with vision
threatening diabetic retinopathy (VTDR) requiring immediate eye care4.
Several national studies since then have shown that prevalence of diabetes is
7.5% to 11% and that of DR and VTDR is 27.43% and 8.73% respectively in
Pakistan5,6. Clinical based evidence shows that control over
modifiable factors like hyperglycaemia7, hypertension8, and
hyperlipidemia9,10 effectively prevent the development and progression
of DR and DME. However this control is not possible in the developing countries
making them more venerable to complications of diabetes. Early detection and
timely treatment of diabetes and DR is necessary to prevent visual impairment. Focal/grid
laser photocoagulation for CSME and Pan retinal photocoagulation (PRP) for PDR
has remained the gold standard for last 30 years after monumental work of Early
Treatment Diabetic Retinopathy Study (ETDRS). Recently anti-VEGF drugs have
become the first line of treatment for CSME11 and Laser therapy
remains an adjuvant therapy to save the frequent visits, whereas PRP is still
the first line of treatment for PDR12. Anti-VEGF before or along
with PRP are of added benefit in high risk cases of PDR13.
This study was designed to show
the visual outcome of various treatment modalities like laser application and
intravitreal Avastin (Bevacizumab) injection as monotherapy or combined in
patients with VTDR in our setup where follow up is poor14.
MATERIAL & METHODS
This was a Quasi Experimental study with
non-probability convenient sampling carried out
at Diabetes eye clinic of Al Ibrahim Eye Hospital (AIEH), Isra Postgraduate
Institute of Ophthalmology, Karachi from January 2016 to December 2017. All the
patients with diabetes mellitus type 2 attending diabetic eye clinic of AIEH
were included in this study. Those with cataract, glaucoma and advanced
diabetic eye disease (ADED) were excluded. Every patient had best corrected
visual acuity (BCVA) recorded along with bio-microscopic examination of
anterior segments and intraocular pressure using Goldman tonometer. They were
all screened with Non Mydriatic Fundus Camera (NMFC) taking one view of the
posterior pole. The patients without DR were examined by a general ophthalmologist
and diabetologist. Patients with any DR or un-readable fundus photograph had
dilated pupil examination with 90 D fundus lens. DR was graded according to
International clinical diabetic retinopathy & macular edema disease
severity scale.15 Patients
with Non vision threatening diabetic retinopathy (NVTDR) were given a follow up
date as per directions of Royal college of ophthalmologist. 16 Patients
with VTDR (PDR and DME) were all considered for intervention. Intervention
advised was either monotherapy laser or intra-vitreal Avastin injection at
monthly interval, or both. Patients with CSME or vitreous hemorrhage (PDR) were
given intra-vitreal Avastin at monthly interval till the macular edema and
hemorrhage were absorbed. It was then followed by modified grid laser for CSME
and PRP for PDR. In DME patients with macular edema away from the fovea,
patients were preferably treated with laser before anti VEGF. Follow up routine
was according to the recommendations of Royal Collage of Ophthalmologist.16
Accordingly the patients receiving
only laser application were advised three to four monthly follow-ups, whereas
patients having intra-vitreal Avastin injections alone or with laser were
advised monthly follow-up, at least in the first year. On each follow-up visit,
BCVA on Log Mar, blood sugar level, lipids and BP were checked.
HbA1C was done in individuals with
labile glycaemia. Optical coherence tomography (OCT) and Fundus Fluorescein
Angiography (FFA) were carried out on all patients requiring treatment. In the
present study, the criteria for labeling improved, stable or worse visual
outcome were single line improvement, no change or decrease on log Mar chart.
Statistical analysis was done
through Statistical Package for social sciences (SPSS) version 23.0. For
continuous variable mean ± Standard deviation were presented. Qualitative
variables were shown in frequency and percentages. To see the significance
between treatment and visual acuity (Improved, stable or worse) Chi-square test
was applied. The significance of Pre & Post visual outcome (Log Mar) was
compared through Paired sample t-test. The cut off value of p ≤ 0.05
considered to be statistically significant.
RESULTS
From January 2016 to December 2017, a total
number of 11,027 patients with diabetes were registered in diabetic clinic. On
screening these patient, 1988 were found to have DR (18.02%) and 586 had VTDR
(5.3%). Amongst the patients with VTDR, 108 (18.3%) had PDR, 382 (65.2%) had
CSME and 96 (16.3%) had ADED. (Table 1) Patients with PDR and CSME (490) were
advised intervention which was accepted by 380 patients with 453 eyes. Laser was done in 78 (17.2%) eyes, Avastin
injection was given in 340 (75.1%) eyes and combined treatments of intra-vitreal
Avastin and Argon laser were given in 35 (7.7%) eyes. Over all BCVA improved in
316 (69.8%) eyes, remained stable in 84 (18.5%) eyes and worsened in 53 (11.7%)
eyes. (Table - II). Pre and post treatment BCVA was noted in Laser, Avastin
injection and combined treatment group. It was observed that laser group showed
improvement in BCVA from Log Mar 0.35 ± 0.23 to 0.24 ± 0.21. In Avastin
injection group improvement was from Log Mar 0.40 ± 0.24 to 0.23 ± 0.20. While
in combined treatment, visual improvement was recorded from Log Mar 0.40 ± 0.24
to 0.20 ± 0.14. Figure 1).
When BCVA was
correlated with treatment modalities separately, Laser group showed visual improvement
in 45 (57.7%) eyes, stable in 18 (23.1%) eyes and worsened in 15 (19.2%) eyes.
The Avastin injection group showed visual improvement in 248 (72.9%) eyes,
stable in 58 (17.1%) eyes and decrease in 34 (10%) eyes. While the group given
combined treatment showed visual improvement in 23 (65.7%) eyes, stable in 8
(22.9%) eyes and worsened in 4 (11.4%) eyes with P-value < 0.0001 (Table 3).
Table 1: Patients attended AIEH during the study
period January 2016 to December 2017.
Description |
Number |
Percentage |
|
Total eye patients in OPD of
AIEH |
225603 |
|
|
Patient with diabetes |
11027 |
4.80% |
|
DR detected |
1988 |
18% |
|
VTDR in all diabetics |
586 |
5.30% |
5.3% in people with diabetes |
PDR, alone |
108 |
5.4% of DR |
0.979% in people with
diabetes, (1.65% when PDR with CSME s included) |
CSME |
382 (79 CSME were
associated with PDR) |
19.2% of DR |
3.464% in people with
diabetes |
ADED |
96 |
16.30% |
0.87% in people with diabetes |
intervention advised |
96 + 110 = 206 out of
586 |
100% |
|
Treatment accepted |
380 persons
(64.8) with 453 eyes |
64.80% |
|
Table
2: Overall
outcome of the treatment.
BCVA Log Mar (n = 453 eyes) |
N (%) |
Improved |
316 (69.8) |
Stable |
84 (18.5%) |
Worse |
53 (11.7%) |
Total |
453 |
*Best
corrected visual acuity (BCVA)
Table 3: Association beteween Diagnosis, treatment and Visual outcome.
Treatment |
BCVA Condition |
Total |
|||
Improved |
Stable |
Worse |
|||
LASER |
CSME |
4 |
4 |
2 |
10 |
40.0% |
40.0% |
20.0% |
100.0% |
||
CSME with NPDR |
14 |
1 |
5 |
20 |
|
70.0% |
5.0% |
25.0% |
100.0% |
||
CSME with PDR |
5 |
0 |
0 |
5 |
|
100.0% |
0.0% |
0.0% |
100.0% |
||
PDR |
22 |
13 |
8 |
43 |
|
51.2% |
30.2% |
18.6% |
100.0% |
||
|
Total |
45 |
18 |
15 |
78 |
|
|
57.7% |
23.1% |
19.2% |
100.0% |
Injection |
CSME |
40 |
13 |
8 |
61 |
65.6% |
21.3% |
13.1% |
100.0% |
||
CSME with NPDR |
133 |
26 |
12 |
171 |
|
77.8% |
15.2% |
7.0% |
100.0% |
||
CSME with PDR |
34 |
15 |
10 |
59 |
|
57.6% |
25.4% |
16.9% |
100.0% |
||
PDR |
41 |
4 |
4 |
49 |
|
83.7% |
8.2% |
8.2% |
100.0% |
||
Total |
248 |
58 |
34 |
340 |
|
72.9% |
17.1% |
10.0% |
100.0% |
||
Both Laser and Injection |
CSME with NPDR |
7 |
0 |
2 |
9 |
77.8% |
0.0% |
22.2% |
100.0% |
||
CSME with PDR |
12 |
3 |
0 |
15 |
|
80.0% |
20.0% |
0.0% |
100.0% |
||
PDR |
4 |
5 |
2 |
11 |
|
36.4% |
45.5% |
18.2% |
100.0% |
||
Total |
23 |
8 |
4 |
35 |
|
65.7% |
22.9% |
11.4% |
100.0% |
||
Total |
CSME |
44 |
17 |
10 |
71 |
62.0% |
23.9% |
14.1% |
100.0% |
||
CSME with NPDR |
154 |
27 |
19 |
200 |
|
77.0% |
13.5% |
9.5% |
100.0% |
||
CSME with PDR |
51 |
18 |
10 |
79 |
|
64.6% |
22.8% |
12.7% |
100.0% |
||
PDR |
67 |
22 |
14 |
103 |
|
65.0% |
21.4% |
13.6% |
100.0% |
||
Total |
316 |
84 |
53 |
453 |
|
69.8% |
18.5% |
11.7% |
100.0% |
Table 4: Comparison of Visual Acuity with different
treatments.
Treatments |
Pre Visual
Acuity |
Post Visual
Acuity |
P-value |
Laser |
0.35 ± 0.23 |
0.24 ± 0.21 |
< 0.001 |
Injection |
0.40 ± 0.24 |
0.23 ± 0.20 |
< 0.001 |
Both |
0.40 ± 0.24 |
0.20 ± 0.14 |
< 0.001 |
*Data
Presented in Mean ± SD, Visual acuity was noticed on Log Mar chart.
*Paired
sample t-test was applied
DISCUSSION
This study showed that BCVA in the laser group
improved by one line or 5 letters (from 0.35±0.23 to 0.24 ± 0.21). Avastin
group showed improvement in BCVA by two lines or 10 letters on Log Mar (from
0.40 ± 0.24 to 0.23 ± 0.20). Visual acuity in combined group improved from 0.40
± 0.24 to 0.20 ± 0.14 (2 lines or ten letters) same as monotherapy with anti-VEGF
group. The present study is in accordance with many studies in favor of
anti-VEGF. Brucker et al17 and Elman et al18 reported that results of anti VEGF vs. PRP in
diabetic retinopathy have better visual acuity, less visual field loss and
fewer surgical interventions in injection groups. Adam et al19 and
Sivaparsad S et al20 has shown the superiority of anti VEGF as the
more effective treatment for preserving visual function associated with DR.
Present study differs from the international studies in loss of patients to
follow up. Adam & Sivaparsad et al (The CLARITY trial)19,20
quoted 9% loss to follow up at 1 year. In the present study 69% were lost to
follow up and only 31% individuals returned for follow-ups. Out of those who
attended, 43.7% attended once, 42.65% attended twice, 4.5% attended thrice,
6.8% attended four times while 2.1% came five times. This raises the question
of cautious use of anti VEGF alone as primary treatment. Anti-VEGF treatment
needs multiple injections at monthly interval. At least three monthly
injections and then monthly follow up for assessing need of repeat injection or
laser is indicated21. Low follow
up compliance mainly due to unawareness, affordability and accessibility in
developing countries22,-24, makes monitoring of anti-VEGF difficult.
In Pakistan, health service uptake is not more than 25%14.
The ultimate result of anti-VEGF may be better
than Laser alone; but it is only possible when patient can afford multiple
injections and visits. In the light of
this study the anti-VEGF combined with laser will be better management of CSME
as well as PDR. With these considerations laser can be considered as first line
of treatment in PDR without macular edema; but if the patient has CSME alone or
with PDR anti VEGF can be the first line of treatment followed by laser.
Visual
outcomes of VTDR after treatment with intra-vitreal Avastin (Bevacizumab) is
superior to PRP alone. Keeping in view the loss to follow ups, we can suggest
PRP in PDR and 1-2 injections of anti-VEGF followed by laser application in
CSME. However larger prospective studies are required to further evaluate the
long term effects of these recommendation in halting the disease progression
and extended improved visual outcomes. However regardless of whatever treatment
is offered to the patient, it is mandatory to educate and adequately address
the importance of regular follow-ups and medical compliance at patients end.
It is important that the physician should keep in mind the cost-affectivity and
affordability of the patient without compromising the outcome of the treatment.
CONCLUSIONS
Visual outcome
of Avastin alone or combined with laser was found to be better than laser
treatment alone in stabilizing the visual acuity in patients with vision
threatening diabetic retinopathy.
Conflict of Interest
The authors
declared that there is no conflict between authors.
Financial Disclosure
None.
Authors
Affiliation
Sidra
Shakil
Senior
Registrar
Isra
Postgraduate institute of ophthalmology
M.
Saleh Memon
Director
research/Executive Director
Isra
Postgraduate institute of ophthalmology
Prof. P
S Mahar
FRCS,
FRCOphth
Professor
& Dean
Isra
Postgraduate institute of ophthalmology
Abdul
Fattah Memon
Professor
Isra
Postgraduate institute of ophthalmology
Muhammad
Faisal Fahin
Statistician
Isra
Postgraduate institute of ophthalmology
Seema N
Mumtaz
Consultant
Epidemiologist
Isra
Postgraduate institute of ophthalmology
Sikandar
Ali Sheikh
Project
Manager
Isra
Postgraduate institute of ophthalmology
Authors
contribution
Sidra
Shakil
Conceive
the study, Manuscript writing.
M.
Saleh Memon
Manuscript
writing, Critical review.
Prof. P
S Mahar
Review
the final manuscript and intellectual contribution.
Abdul
Fattah Memon
Clinical
evaluation and management of patients.
Muhammad
Faisal Fahin
Statistical
analysis and Interpretation.
Seema N
Mumtaz
Review
and final drafting of manuscript.
Sikandar
Ali Sheikh
Data
collection, study design and review.
REFERENCES
1. Early
Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for
diabetic macular edema. Early Treatment Diabetic Retinopathy Study report
number 1. Archives of Ophthalmology, 1985; 103 (12): 1796 1806.
2. Yau
JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T et al. Global
Prevalence and Major Risk Factors of Diabetic Retinopathy. Diabetes Care, 2012;
35: 556564.
3. Jadoon
MZ, Dineen B, Bourne RA, Shah SP, Khan MA, Johnson GJ et al. Prevalence of
Blindness and Visual Impairment in Pakistan: The Pakistan National Blindness
and Visual Impairment Survey. Investigative Ophthalmol& Vis Sci. 2006; 47
(11): 4749-55.
4. Groves
N. Diabetic retinopathy on the rise in Pakistan, Investigative
Ophthalmol& Vis Sci. 2006; 47 (11): 4749-55.
5. Hakeem
R, Fawwad A. Diabetes in Pakistan: Determinants and Prevention. Journal of Diabetology, October, 2010; 1 (3):
1-13.
6. Mumtaz
SN, Fahim MF, Arslan M, Shaikh SA, Kazi U, Memon MS. Prevalence of diabetic
retinopathy in Pakistan: A systematic review. Pak J Med Sci. 2018; 34 (2): 493-500.
7. UK
Prospective Diabetes Study Group: Intensive blood-glucose control with
sulphonylureas or insulin compared with conventional treatment and risk of
complications in patients with type 2 diabetes: UKPDS 33. Lancet. 1998; 352: 837853.
8. UK
Prospective Diabetes Study Group: Efficacy of atenolol and captopril
in reducing risk of macrovascular and microvascular complications in type 2
diabetes: UKPDS 39. Br Med J. 1998; 317: 713720.
9. Klein
BEK, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of
Diabetic Retinopathy, XIII: relationship of serum cholesterol to retinopathy
hard exudate. Ophthalmology, 1991; 98: 1261 1265.
10. Gordon
B, Chang S, Kavanagh M, Berrocal M, YannuzziL, Robertson C et al. The
effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol. 1991; 112: 385391.
11. Bhagat
N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis
and treatment. Surv Ophthalmol. 2009; 54 (1): 1-32.
Doi: 10.1016/j.survophthal.2008.10.001.
12. The Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic
retinopathy: Diabetic Retinopathy Study Report no. 14. Int Ophthalmol Clin.
1987; 27: 239253.
13. Osaadon P, Fagan XJ, Lifshitz T, Levy J. A review of anti-VEGF agents for proliferative diabetic
retinopathy. Eye (Lond). 2014; 28 (5): 510520.
14. Alvi
R, Memon MS, Shera S, Mumtaz SN, Shaikh SA, Fahim MF. Visual outcome of
laser treatment in diabetic macular edema: Study from an Urban Diabetes Care Center.
Pak J Med Sci. 2016; 32 (5): 1229-1233.
Doi: http://dx.doi.org/10.12669/pjms.325.10597
15. Wilkinson
CP, Ferris FL, Klien RE, at al. Proposed International Clinical diabetic
retinopathy and diabetic macular edema disease severity scales. Ophthalmology,
2003; 110 (9): 1677-82.
16. Ghanchi F. A summary and the Diabetic Retinopathy Guidelines
Working Group. The Royal College of Ophthalmologists' clinical guidelines for
diabetic retinopathy, 2013; 27 (2):
285287.
17. Brucker
AJ, Qin H, Antoszyk AN, et al. Diabetic Retinopathy Clinical Research
Network. Observational study of the development of diabetic macular edema
following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol. 2009; 127 (2): 132-140.
18. Elman
MJ, Aiello LP, Beck RW, et al. Diabetic Retinopathy Clinical Research
Network. Randomized trial evaluating ranibizumab plus prompt or deferred
laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology, 2010; 117 (6): 1064-1077.
19. Adam
R. Glassman, MS1. Results of a Randomized Clinical Trial of Aflibercept vs.
Panretinal Photocoagulation for Proliferative Diabetic Retinopathy Is It Time
to Retire Your Laser? JAMA Ophthalmol. 2017; 135 (7): 685-686.
20. Sivaprasad
S, Prevost AT,Vasconcelos JC, Riddell A, Murphy C, Kelly J et al. Clinical
efficacy of intravitreal aflibercept versus panretinal photocoagulation for
best corrected visual acuity in patients with proliferative diabetic
retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised,
controlled, phase 2b, non-inferiority trial. The Lancet. 2017; 389 (10085):
21932203.
21. Michaelides
M, Kaines A, Hamilton RD. A prospective randomized trial of intravitreal bevacizumab
or laser therapy in the management of diabetic macular edema (BOLT study)
12-month data: report 2. Ophthalmology, 2010; 117 (6): 10781086.
22. Hakeem
R, Awan Z, Memon S, Gillani M, Shaikh SA, Sheikh MA, et al. Diabetic
retinopathy awareness and practices in a low-income suburban population in
Karachi, Pakistan. J Diabetol. 2017; 8: 49-55.
23. Memon
MS, Mumtaz SN, Sheikh SA, Fahim MF. Community Perception and Service
Utilization of Diabetic Retinopathy Management Project in Gaddap Town. Pak J Ophthalmol. 2016; 32 (2): 70-77.
24. Memon
MS, Shaikh SA, Shaikh AR, Fahim MF, Mumtaz SN, Ahamad N. An assessment of
Knowledge, attitude & Practices (KAP) towards Diabetes & Diabetic
retinopathy in suburban town of Karachi. Pak J Med Sc. 2015; 3191): 183-188.